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ABSTRACT
Introduction: The pharmacokinetics of
vancomycin are highly variable among
neonates, which makes dosing challenging in
this population. However, adequate drug
exposure is critical, especially when treating
methicillin-resistant Staphylococcus aureus
(MRSA) infections. Utilization of population
pharmacokinetic models and Bayesian
methods offers the potential for developing
individualized therapeutic approaches. To
meet this need, a neonatal vancomycin
population pharmacokinetic model was
recently published. The current study sought
to externally evaluate the predictive
performance and generalizability of this model.
Methods: A retrospective chart review of
neonates who received vancomycin and had
C1 peak and C1 trough concentrations at five
Intermountain Healthcare neonatal intensive
care units from 2006 to 2013 was performed and
served as the external validation cohort. The
published population pharmacokinetic model
was implemented in NONMEM 7.2 with the
structural and variance parameter values set
equal to the estimates reported previously. The
model was then used to predict the first peak
and trough concentration for each neonate in
the validation cohort and the model prediction
error and absolute prediction error were
calculated. Normalized prediction distribution
errors (NPDE) were also evaluated.
Results: A total of 243 neonates were studied
with a median postmenstrual age of 33 (range:
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23–54) weeks and a median weight of 1.6
(range: 0.4–6.8) kg. The model predicted the
observed vancomycin concentrations with
reasonable precision. For all vancomycin
concentrations, the median prediction error
was -0.8 (95% CI: -1.4 to -0.4) mg/L and the
median absolute prediction error was 3.0 (95%
CI: 2.7–3.5) mg/L. No trends in NPDE across
weight, postmenstrual age, serum creatinine, or
time after dose were observed.
Conclusion: An evaluation of a recently
published neonatal vancomycin population
pharmacokinetic model in a large external
dataset supported the predictive performance
and generalizability of the model. This model
may be useful in evaluating neonatal
vancomycin dosing regimens and estimating
the extent of drug exposure.




Optimizing vancomycin dosing to rapidly
achieve adequate drug exposure is imperative
in treating neonatal sepsis, particularly when
treating invasive methicillin-resistant
Staphylococcus aureus (MRSA) infections [1].
However, this has been challenging in
neonates as the pharmacokinetics of
vancomycin are highly variable among
neonates due to developmental and
pathophysiological changes [2, 3]. Recent
studies have shown that standard neonatal
vancomycin dosing strategies, such as those
outlined in NeoFax (Truven Health
Analytics), do not reliably achieve trough
concentrations [10 mg/L [4, 5]. In addition,
the ratio of the 24-h area under the
concentration–time curve (AUC24) to the
minimum inhibitory concentration (MIC)—
the best predictor of successful outcomes
when treating invasive MRSA infections—is
not routinely utilized to assess the
appropriateness of vancomycin dosing in
neonates, presumably due to practical
limitations associated with calculating the
AUC24.
Innovative vancomycin dosing strategies are
therefore needed in neonates that: (1)
incorporate known patient-specific
determinants of vancomycin pharmacokinetics
such as size, maturation, and renal function in
the dose selection, and (2) allow for assessment
of AUC24 based on the dosing history and
vancomycin concentration(s) measured as part
of routine therapeutic drug monitoring [3, 6, 7].
To develop such an individualized therapeutic
approach in neonates, utilization of population
pharmacokinetic models and Bayesian methods
will be essential [8–11]. We recently developed
a neonatal vancomycin population
pharmacokinetic model that capitalized on
patient data readily available in the electronic
medical record: weight (an indicator of size),
postmenstrual age (an indicator of maturation),
and serum creatinine (an indicator of renal
function) [7]. The model has the potential to
improve our ability to define vancomycin
dosing regimens that reliably achieve
recommended exposure targets; however, it is
critical to first evaluate whether this model and
its findings are generalizable to neonates
outside of the original population used to
develop the model. The objective of the
current study was to conduct an external
evaluation of this published pharmacokinetic
model and to enhance our understanding of the
relationship between vancomycin trough
concentration and AUC24 in neonates.
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METHODS
Validation Cohort
Approval to conduct this study was granted by
the University of Utah and Primary Children’s
Hospital (PCH) Institutional Review Boards.
PCH is a freestanding children’s hospital with
a level IV neonatal intensive care unit that is
staffed by University of Utah neonatologists.
PCH is owned and operated by Intermountain
Healthcare, which is a large, not-for-profit,
vertically integrated healthcare delivery system
that serves Utah, Idaho, Wyoming, Nevada, and
Montana. In addition to PCH, four other level
II-III neonatal intensive care units operated by
Intermountain Healthcare were included in this
study.
A retrospective chart review was conducted
for all neonates who had vancomycin
therapeutic drug monitoring performed from
2006 to 2013 at five Intermountain Healthcare
neonatal intensive care units. Neonates were
included if they were\54 weeks postmenstrual
age and had C2 doses of vancomycin, C1 peak
concentration, C1 trough concentration, and
C1 serum creatinine level. Vancomycin
concentrations were quantified using a
particle-enhanced turbidimetric inhibition
immunoassay on an Abbott Architect System
platform (Abbott Laboratories, Abbott Park, IL,
USA). Vancomycin concentrations were defined
based on their temporal relationship to dosing
records. Trough concentrations were defined as
concentrations obtained within 3 h of the next
vancomycin dose and peak concentrations were
defined as concentrations obtained within 3 h
of the preceding dose. Serum creatinine levels
collected within ±48 h of vancomycin dosing
and concentration records were carried forward
and backward and were used in the analyses. To
account for the known difference in measured
serum creatinine concentrations between the
Jaffe method (used in the original model
derivation cohort) and the enzymatic method
(used in the current external validation cohort),
a previously described linear conversion factor
was applied to all of the enzymatic serum
creatinine concentrations included in this
external validation (enzymatic concentration
¼ 1:050  Jaffe method concentration  0:122)
[12]. Exclusion criteria included a diagnosis of
congenital kidney disease, major congenital
heart disease (other than ventricular septal
defect, atrial septal defect, or patent ductus
arteriosus), or extracorporeal membrane
oxygenation during the vancomycin course.
Model Evaluation
The published neonatal vancomycin
population pharmacokinetic model was
implemented in the non-linear mixed effects
modeling software NONMEM 7.2 (ICON
Development Solutions, Ellicott City, MD,
USA) as previously described [7]. Briefly, a one
compartment model with first-order
elimination was used to describe vancomycin
pharmacokinetics. Clearance (CL) was
predicted by weight (an indicator of size),
postmenstrual age (PMA; an indicator of
maturation) and serum creatinine (Cr; an










Volume of distribution (V) was predicted by
weight:
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After accounting for known predictors, the
remaining variation between neonates was
described by an exponential error model for
both CL (% coefficient of variation [% CV]
21.6%) and V (% CV 10.9%). Residual variability
(a measure of the difference between the model
predicted concentration for a neonate and the
observed concentration in that neonate) was
captured using a combined proportional (% CV
20.5%) and additive error model (standard
deviation [SD] ± 1.3 mg/L).
For each neonate in the external validation
cohort, vancomycin concentrations were then
predicted using the parameters of the population
pharmacokinetic model and simulating the actual
dosing regimen given to the neonate (using the
NONMEM MAXEVAL= 0 POSTHOC command).
Only concentrations at times for which a neonate
had therapeutic drug monitoring performed were
simulated. Model predicted vancomycin
concentrations (PRED from the NONMEM
output) were then compared with the
corresponding observed vancomycin
concentrations. As described by Sheiner and Beal
[13], the bias and precision of the model were
assessed by calculating the median prediction
error and median absolute prediction error for
the first trough and peak concentration according
to the following formulas:











where Concpred refers to the model predicted
vancomycin concentration and Concobs refers
to the observed vancomycin concentration.
Model predicted vancomycin concentrations
calculated using each patient’s individual
Bayesian estimate of CL and V (i.e., the IPRED
from the NONMEM output, which incorporates
the patient’s drug concentrations in addition to
the fixed covariate effects in the model
predictions) were also evaluated using the
same approach.
The predictive performance of the model was
further evaluated using simulation-based
diagnostic methods. Normalized prediction
distribution errors (NPDE) were calculated by
simulating 1,000 data sets and comparing the
predicted concentrations to the observed
concentrations using the NPDE command in
NONMEM [14, 15]. The NPDE should follow a
normal distribution with a theoretical mean of
0 and variance equal to 1 [14].
Trough Concentration and AUC24
Relationship
Following model evaluation, the relationship
between trough concentration and AUC24 was
examined. Bayesian estimates of CL for each
neonate from the population pharmacokinetic
model were used to calculate AUC24 at the time
that vancomycin trough concentrations were
collected [8]. AUC24 was calculated as the daily
dose 7 CL. For a given trough concentration,
the proportion of neonates with that trough
concentration who achieved an AUC24 C400
was calculated. An AUC24 C400 mg 9 hr/L
would predict an AUC24/MIC C400 for an MIC
of B1 mg/L. AUC24 calculations, descriptive
statistics, and graphical analyses were
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performed in R 3.1.1 (R Foundation for
Statistical Computing, Vienna, Austria).
RESULTS
External Validation Cohort
Overall, 243 neonates had vancomycin dose
and concentration data available and served as
the external validation cohort (see Fig. S1 in the
electronic supplementary material [ESM]). The
median dose was 15.5 (interquartile range
[IQR]: 13.9–19.3) mg/kg and the median
dosing interval was 11.5 (IQR: 8.0–12.5) h.
Demographic and clinical characteristics of the
neonates in the external validation cohort are
shown in Table 1. For comparison,
demographic and clinical characteristics of the
neonates in the cohort used to develop the
original published pharmacokinetic model are
also shown. Overall, the validation cohort was
of lower weight and age and had higher serum
creatinine concentrations.
In the external validation cohort, a total of
734 vancomycin concentrations were available
for analysis. Each neonate contributed a mean
of 3.0 (±1.8) vancomycin concentrations. The
time of vancomycin concentration collection
relative to the previous dose is shown in
Table 2. All neonates had at least one
concentration measured within three hours of
the end of the vancomycin infusion. No
concentrations were below the lower limit of
quantitation.
Model Evaluation
The vancomycin pharmacokinetic model
adequately described the observed vancomycin
concentrations in the external cohort of
Table 1 Demographic and clinical characteristics of neonates who received vancomycin and had therapeutic drug
monitoring performed
Characteristic Model development cohort (n5 249)a External validation cohort (n5 243)b
Median/No. Range Median/No. Range
Female, n (%) 121 (49%) – 103 (42%) –
Gestational age, weeks 34 23–42 30 22–41
Birth weight, kg 2.0 0.4–4.4 1.3 0.5–5.1
Weight, kg 2.9 0.5–6.3 1.6 0.4–6.8
Postnatal age, days 19 0–173 12 0–196
Postmenstrual age, weeks 39 24–53 33 23–54
APGAR at 5 min 8 1–10 8 1–10
Serum creatinine, mg/dLd 0.4 0.1–2.7 0.6 0.3–1.5
APGAR Newborn scale based on Appearance, Pulse, Grimace, Activity, and Respiration
a Patient characteristics of the 249 neonates used to develop the neonatal vancomycin population pharmacokinetic model
described by Frymoyer et al. [7]
b Patient characteristics of the 243 neonates used in the current external validation
c The serum creatinine concentration in the model derivation cohort was measured using the Jaffe method. The serum
creatinine concentration in the external validation cohort was measured using the enzymatic method and was converted to a
Jaffe-standardized equivalent using a linear equation described by Srivastava et al. [12]. Converted values are presented in the
table above
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neonates (Fig. 1a). Model predicted vancomycin
concentrations (PRED) were slightly lower
than the observed concentrations (median
prediction error -0.8 [95% CI: -1.4 to
-0.4] mg/L). The precision of the model was
reasonable with a median absolute prediction
error of 3.1 (95% CI: 2.7–3.2) mg/L. The
predictive performance of the model for peak
and trough concentrations is featured in
Table 3. When incorporating patient
concentrations to obtain Bayesian estimates of
pharmacokinetic parameters for each neonate,
the precision of the model predicted
vancomycin concentrations (IPRED) improved
(Table 4). For example, the median IPRED
absolute prediction error was 1.7 (95% CI:
1.5–1.8) mg/L.
Simulation-based diagnostics of the
vancomycin pharmacokinetic model
demonstrated a mean NPDE of 0.05 and a
variance of 0.96, indicating no bias and an
ability of the model to reasonably capture the
underlying variability in the external validation
cohort. Additionally, there were no trends in
NPDE across weight, postmenstrual age, serum
creatinine, or time after dose (Fig. 2).
Fig. 1 An external evaluation of the predictive perfor-
mance of a previously published neonatal vancomycin
population pharmacokinetic model [7]. a Diagnostic plot
depicting the model ﬁt for observed versus population
predicted vancomycin concentrations. The dashed black line
represents the locally weighted scatterplot smoothed ﬁt of
the data. b Kernel density plot of the normalized prediction
distribution errors with a histogram depicting a normal,
Gaussian distribution overlaid for comparative purposes
Table 2 Timing of 734 neonatal vancomycin
concentrations relative to the end of the most recent 1-h
infusion
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Trough Concentration and AUC24
Relationship
A linear relationship between increased AUC24
and higher trough concentrations was observed
in the external validation cohort (r2 = 0.60;
Fig. 3a). AUC24 was highly variable at a given
trough concentration (i.e., a two- to threefold
range of AUC24 was achieved at a given trough
concentration), and therefore, AUC24 could not
Table 3 Predictive performance of the neonatal population pharmacokinetic model in the external validation cohort
Predictive measure All concentrations First peak First trough
Prediction error
Median -0.8 -2.0 -0.1
95% conﬁdence interval -1.4 to -0.4 -2.9 to -1.4 -0.5 to 0.2
Percent prediction error
Median -4.5% -7.5% -1.5%
95% conﬁdence interval -7.2% to -2.2% -9.4% to -4.9% -4.5% to 2.7%
Absolute prediction error
Median 3.0 3.9 2.1
95% conﬁdence interval 2.7 to 3.5 3.4 to 4.1 1.7 to 2.7
Absolute percent prediction error
Median 15.2% 12.6% 20.1%
95% conﬁdence interval 14.1% to 17.3% 10.9% to 14.4% 16.8% to 24.0%
Table 4 Predictive performance of the neonatal population pharmacokinetic model in the external validation cohort after
incorporating patient drug concentrations in predictions (e.g., IPRED method)
Predictive measure All concentrations First peak First trough
Prediction error
Median -0.7 -1.7 -0.2
95% conﬁdence interval -0.9 to -0.5 -2.2 to -1.4 -0.4 to 0.1
Percent prediction error
Median -3.8% -5.8% -1.7%
95% conﬁdence interval -4.9% to -3.2% -7.5 to -4.6% -3.4% to 0.6%
Absolute prediction error
Median 1.7 2.7 0.9
95% conﬁdence interval 1.5 to 1.8 2.1–3.1 0.7–1.1
Absolute percent prediction error
Median 8.8% 8.4% 9.1%
95% conﬁdence interval 8.1–9.7% 7.3–9.6% 7.3% to 10.8%
Infect Dis Ther (2015) 4:187–198 193
be precisely predicted for an individual neonate
based on a trough concentration alone.
However, a trough concentration of 11 mg/L
predicted the achievement of an AUC24 C400 in
93% of neonates (Fig. 3b). The median (range)
AUC24 at this trough concentration was
542 (308 to 649) mg 9 hr/L.
DISCUSSION
External validation of a population
pharmacokinetic model is described by the
United States Food and Drug Administration
as ‘‘the most stringent method for testing a
developed model’’ [16]. Yet, external validation
Fig. 2 Assessment of the predictive performance of the
neonatal vancomycin population pharmacokinetic model.
a Normalized prediction distribution errors versus weight,
measured in kilograms. b Normalized prediction distribu-
tion errors versus the time elapsed since the last vancomycin
dose, measured in hours. c Normalized prediction
distribution errors versus postmenstrual age, measured in
weeks. d Normalized prediction distribution errors versus
serum creatinine concentrations, measured in milligrams
per deciliter. The dashed black lines represent locally
weighted scatterplot smoothed ﬁts of the data
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is performed in \10% of published
pharmacokinetic models and concerns about
the clinical utility of the model often remain
[17]. The external validation performed in the
current study strengthens a previously
published neonatal vancomycin population
pharmacokinetic model. Namely, we found
the pharmacokinetic model to be unbiased
across the largest cohort of neonates used in a
validation study to date. The precision of the
model when utilizing only a neonate’s
postmenstrual age, weight, and serum
creatinine was 12.6% for peak concentrations
and 20.1% for trough concentrations. When a
neonate’s drug concentrations are incorporated
into the model (such as would occur after
therapeutic drug monitoring in the NICU), the
precision further improved to 8.4 and 9.1% for
peak and trough concentrations, respectively.
This level of precision suggests that the model
may be useful in evaluating vancomycin dosing
regimens and estimating the extent of drug
exposure in the clinical setting.
A recent clinical study by Ringenberg et al.
[4] highlights the current challenges with
vancomycin dosing in neonates. In a
multicenter retrospective evaluation,
vancomycin dosing guidelines from Neofax
resulted in only 25% of the neonates studied
achieving a target trough concentration of
10–20 mg/L with empiric dosing [4]. Moreover,
the authors reported that 20% of the neonates
included in their study had a trough
concentration \5 mg/L (Theresa Ringenberg,
personal communication, April 15, 2015).
Even after therapeutic drug monitoring and
dose adjustment, only 45% of neonates
achieved the goal trough concentration of
10–20 mg/L at any point during their course of
therapy. This study clearly reveals the
Fig. 3 The association between vancomycin trough con-
centrations and the extent of drug exposure, as measured by
the 24-h area under the curve (AUC24). a Higher
vancomycin trough concentrations were associated with
higher AUC24 values, although substantial variability was
noted. b The probability of achieving a pharmacokinetic/
pharmacodynamic target associated with clinical and
microbiological success for invasive methicillin-resistant
Staphylococcus aureus infections (an AUC24 C400) in-
creased with higher vancomycin trough concentrations. All
neonates with a trough C12 mg/L had an AUC24 C400,
although many neonates achieved the AUC24 target with
lower trough concentrations
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significant clinical challenge associated with
reliably achieving therapeutic and safe
vancomycin concentrations in this highly
variable patient population [4]. More
innovative vancomycin dosing strategies and
approaches are needed in neonates that can
help providers personalize empiric dose
selection, interpret therapeutic drug
monitoring data, and adjust dosing so that
exposure targets are achieved.
Population pharmacokinetic models are a
powerful tool that can aid clinicians and help
inform dosing decisions [18, 19]. By
incorporating patient-specific characteristics,
dosing information, drug concentrations, and
consideration of the variability between
patients, population pharmacokinetic models
offer the opportunity to provide a more
personalized approach to therapeutic decision
making. This is especially valuable in a highly
variable population, such as neonates, receiving
a narrow therapeutic window drug such as
vancomycin.
In adults, Bayesian approaches utilizing
population pharmacokinetic models have
already been shown to have the potential to
help support vancomycin dosing decisions [19,
20]. Advancement of similar approaches in
neonates is needed. The development and
external validation of a neonatal vancomycin
population pharmacokinetic model lays the
foundation for this future work. For example,
our group is currently developing a model-
based approach to individualize the empiric
dose in neonates that incorporates the
predictors of weight, postmenstrual age, and
serum creatinine. Using a simulation
framework, the vancomycin dose for a given
neonate that is most likely to achieve an AUC24
C400 while still maintaining a trough
concentration \20 mg/L is calculated. A user-
friendly, web-based application is currently
being developed to facilitate the adoption of
this model in our neonatal intensive care units,
including integration into the electronic health
record. In addition, the ability to estimate
AUC24 and assist providers with dose
adjustment within the clinical workflow would
be of high value.
Until more robust clinical dosing support
tools are developed, clinicians will continue to
rely on trough concentration monitoring to
help guide vancomycin dosing in neonates. Our
findings reinforce the large variability observed
in vancomycin trough concentrations among
neonates and the inability of a trough
concentration alone to reliably predict an
individual neonate’s AUC24. Targeting an
AUC24/MIC C400 is recommended by the
Infectious Disease Society of America when
treating invasive MRSA infections and a
trough concentration of 15–20 mg/L is
suggested in adults to achieve this target [1,
21]. The current study provides further support
that in neonates a vancomycin trough
concentration of 15–20 mg/L is unnecessary to
achieve an AUC24/MIC C400 with an MIC
B1 mg/L and that lower trough concentrations
are likely adequate based on AUC24
considerations [7]. Accordingly, a trough
concentration of approximately 10 mg/L is
likely a reasonable first-line target that will
provide adequate exposure for invasive MRSA
while also appropriately covering for coagulase
negative staphylococcal infections. Further dose
adjustment and individualization of the
therapeutic approach should be guided by the
specific pathogen identified, susceptibility
testing, clinical status, etc. For example, for
MRSA infections with MICs C2 mg/L, an
alternative to vancomycin may be necessary
since an AUC24/MIC C400 will not be achieved
in neonates even at trough concentrations of
15–20 mg/L [7]. Lastly, the extent to which the
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target AUC24/MIC C400 is generalizable to
neonates is unclear and requires further study.
CONCLUSIONS
In summary, an evaluation of a recently
published neonatal vancomycin population
pharmacokinetic model in a large external
dataset supported the predictive performance
and generalizability of the model. The model
may be useful in evaluating vancomycin dosing
regimens and for estimating the extent of drug
exposure in neonates.
ACKNOWLEDGMENTS
The authors received financial support from the
American Foundation for Pharmaceutical
Education, Primary Children’s Hospital
Foundation, and the National Institutes of
Health, which supported their effort spent
conducting this study as noted in the conflict
of interest section. No funding or sponsorship
was received for the publication of this article.
All named authors meet the International
Committee of Medical Journal Editors (ICJME)
criteria for authorship for this manuscript, take
responsibility for the integrity of the work as a
whole, and have given final approval for the
version to be published.
Conflict of interest. CS is supported by the
American Foundation for Pharmaceutical
Education’s Clinical Pharmaceutical Sciences
Fellowship. JKR is supported by the
Pharmacotherapy Subspecialty Award from the
Primary Children’s Hospital Foundation. AF is
supported by the National Institutes of Health
(NICHD 1K23HD079557). ALH is supported by
the National Institutes of Health (NICHD
K08HS023320). JB, EKK, MGS, and CMTS
declare that they have no conflicts of interest.
Compliance with ethics guidelines. All
procedures followed were in accordance with
the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1975, as revised in
2013. A waiver of informed consent was
granted by the Institutional Review Boards of
the University of Utah and Primary Children’s
Hospital for the retrospective data presented in
this study.
Open Access. This article is distributed
under the terms of the Creative Commons
Attribution Noncommercial License which
permits any noncommercial use, distribution,
and reproduction in any medium, provided the
original author(s) and the source are credited.
REFERENCES
1. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice
guidelines by the infectious diseases society of
america for the treatment of methicillin-resistant
Staphylococcus aureus infections in adults and
children. Clin Infect Dis An Off Pub Infect Dis Soc
Am. 2011;52(3):e18–55.
2. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey
DL, Leeder JS, Kauffman RE. Developmental
pharmacology–drug disposition, action, and
therapy in infants and children. New Eng J Med.
2003;349(12):1157–67.
3. Stockmann C, Roberts JK, Yu T, et al. Vancomycin
pharmacokinetic models: informing the clinical
management of drug-resistant bacterial infections.
Expert Rev Anti Infect Ther. 2014;12(11):1371–88.
4. Ringenberg T, Robinson C, Meyers R, et al.
Achievement of therapeutic vancomycin trough
serum concentrations with empiric dosing in
neonatal intensive care unit patients. Pediat Infect
Dis J; 2015; (Epub ahead of print).
Infect Dis Ther (2015) 4:187–198 197
5. Vandendriessche A, Allegaert K, Cossey V, Naulaers
G, Saegeman V, Smits A. Prospective validation of
neonatal vancomycin dosing regimens is urgently
needed. Curr Ther Res Clin Exp. 2014;76:51–7.
6. Jacqz-Aigrain E, Zhao W, Sharland M, van den
Anker JN. Use of antibacterial agents in the
neonate: 50 years of experience with vancomycin
administration. Sem Fetal Neo Med.
2013;18(1):28–34.
7. Frymoyer A, Hersh AL, El-Komy MH, et al.
Association Between Vancomycin Trough
Concentration and AUC in Neonates. Antimicr
Agents Chemother; 2014.
8. Sheiner LB, Beal S, Rosenberg B, Marathe VV.
Forecasting individual pharmacokinetics. Clin
Pharmacol Ther. 1979;26(3):294–305.
9. Sheiner LB, Rosenberg B, Melmon KL. Modelling of
individual pharmacokinetics for computer-aided
drug dosage. Comput Biomed Res Int J.
1972;5(5):411–59.
10. Sheiner LB, Beal SL. Bayesian individualization of
pharmacokinetics: simple implementation and
comparison with non-Bayesian methods. J Pharm
Sci. 1982;71(12):1344–8.
11. Schumacher GE, Barr JT. Bayesian approaches in
pharmacokinetic decision making. Clin Pharm.
1984;3(5):525–30.
12. Srivastava T, Alon US, Althahabi R, Garg U. Impact
of standardization of creatinine methodology on
the assessment of glomerular filtration rate in
children. Pediatr Res. 2009;65(1):113–6.
13. Sheiner LB, Beal SL. Some suggestions for
measuring predictive performance.
J Pharmacokinet Biopharm. 1981;9(4):503–12.
14. Brendel K, Comets E, Laffont C, Laveille C, Mentre
F. Metrics for external model evaluation with an
application to the population pharmacokinetics of
gliclazide. Pharm Res. 2006;23(9):2036–49.
15. Brendel K, Comets E, Laffont C, Mentre F.
Evaluation of different tests based on observations
for external model evaluation of population
analyses. J Pharmacokinet Pharmacodyn.
2010;37(1):49–65.
16. US FDA. Guidance for industry: population
pharmacokinetics [online]. Available from: http://
www.fda.gov/downloads/Drugs/Guidances/UCM07
2137.pdf. Accessed 18 Sep 2014.
17. Brendel K, Dartois C, Comets E, et al. Are
population pharmacokinetic and/or
pharmacodynamic models adequately evaluated?
A survey of the literature from 2002 to 2004. Clin
Pharmacokinet. 2007;46(3):221–34.
18. Lee JY, Garnett CE, Gobburu JV, et al. Impact of
pharmacometric analyses on new drug approval
and labelling decisions: a review of 198 submissions
between 2000 and 2008. Clin Pharmacokinet.
2011;50(10):627–35.
19. Neely MN, Youn G, Jones B, et al. Are vancomycin
trough concentrations adequate for optimal
dosing? Antimicrob Agents Chemother.
2014;58(1):309–16.
20. Nunn MO, Corallo CE, Aubron C, Poole S, Dooley
MJ, Cheng AC. Vancomycin dosing: assessment of
time to therapeutic concentration and predictive
accuracy of pharmacokinetic modeling software.
Annal Pharmacother. 2011;45(6):757–63.
21. Rybak MJ, Lomaestro BM, Rotschafer JC, et al.
Vancomycin therapeutic guidelines: a summary of
consensus recommendations from the infectious
diseases Society of America, the American Society of
Health-System Pharmacists, and the Society of
Infectious Diseases Pharmacists. Clin Infect Dis An
Off Pub Infect Dis Soc Am. 2009;49(3):325–7.
198 Infect Dis Ther (2015) 4:187–198
